|
Variables
|
Overall survival
|
Progression-free survival
|
|---|
|
HR (95% CI)
|
P
|
HR (95% CI)
|
P
|
|---|
|
A (univariate)
|
|
Gender
|
|
Male
|
1.88 (0.89–3.97)
|
0.094
|
2.16 (1.10–4.23)
|
0.025
|
|
Female
|
1
| |
1
| |
|
Age (years)
|
|
≥ 60
|
1.23 (0.60–2.54)
|
0.565
|
1.12 (0.58–2.13)
|
0.731
|
|
< 60
|
1
| |
1
| |
|
Smoking status
|
|
Ever smokers
|
1.73 (0.84–3.55)
|
0.136
|
1.60 (0.84–3.04)
|
0.147
|
|
Never smokers
|
1
| |
1
| |
|
cStage
|
|
IV
|
1.05 (0.25–4.45)
|
0.940
|
0.76 (0.23–2.49)
|
0.658
|
|
III
|
1
| |
1
| |
|
Tumor differentiation
|
|
Poor
|
1.90 (0.88–4.11)
|
0.101
|
1.75 (0.89–3.45)
|
0.103
|
|
Well/moderate
|
1
| |
1
| |
|
Performance status
|
|
1–2
|
1.68 (0.64–4.41)
|
0.291
|
1.97 (0.82–4.73)
|
0.129
|
|
0
|
1
| |
1
| |
|
B
|
0.99 (0.92–1.07)
|
0.818
|
0.93 (0.86–1.06)
|
0.677
|
|
NK
|
1.01 (0.96–1.05)
|
0.892
|
0.96 (0.91–1.02)
|
0.645
|
|
NKT
|
0.87 (0.58–1.09)
|
0.583
|
0.68 (0.36–1.07)
|
0.328
|
|
γδT
|
0.94 (0.85–1.05)
|
0.298
|
0.95 (0.86–1.04)
|
0.295
|
|
CD8+CD28+
|
0.52 (0.25–0.92)
|
0.013
|
0.59 (0.29–0.96)
|
0.016
|
|
CD8+CD28−
|
0.93 (0.79–1.12)
|
0.349
|
0.98 (0.95–1.02)
|
0.314
|
|
CD28+/CD28−
|
1.08 (0.69–1.68)
|
0.735
|
1.00 (0.68–1.47)
|
0.991
|
|
CD4+CD25hi
|
1.57 (0.88–2.46)
|
0.153
|
1.96 (1.22–2.81)
|
0.011
|
|
B (multivariate)
|
|
Gender
|
1.92 (0.82–4.49)
|
0.133
|
2.12 (0.99–4.57)
|
0.055
|
|
CD8+CD28+
|
0.51 (0.30–0.89)
|
0.021
|
0.66 (0.37–0.93)
|
0.038
|
|
CD4+CD25hi
|
–
|
–
|
1.53 (1.19–1.97)
|
0.031
|
- P-values for multivariate analyses are adjusted. The HR and 95% CI were reported for 1 SD increase for immune cells
